Conclusions
In this randomized, controlled, equivalence and noninferiority trial of patients with ACS in the acute phase, the use of short-term rivaroxaban (5 mg twice daily) was noninferior to enoxaparin in terms of both safety and efficacy outcomes in addition to DAPT. The data obtained from this small trial might be helpful for designing future noninferiority trials with sufficient sample sizes to test whether rivaroxaban 5 mg twice daily plus DAPT might be a reasonable alternative regimen to enoxaparin plus DAPT during the acute phase of ACS for patients who missed the primary reperfusion window or not.